Indivior PLC (INDV) PT Lowered to GBX 395
Indivior PLC (LON:INDV) had its price target cut by equities researchers at Deutsche Bank AG from GBX 400 ($5.22) to GBX 395 ($5.16) in a research report issued on Tuesday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Deutsche Bank AG’s price objective points to a potential upside of 26.12% from the stock’s previous close.
Other equities analysts also recently issued research reports about the company. Jefferies Group reissued a “buy” rating and set a GBX 245 ($3.20) price target on shares of Indivior PLC in a research report on Monday, June 6th. Stifel Nicolaus boosted their price target on Indivior PLC from GBX 310 ($4.05) to GBX 350 ($4.57) and gave the stock a “buy” rating in a research report on Monday, July 11th. Finally, Numis Securities Ltd reissued a “buy” rating and set a GBX 340 ($4.44) price target on shares of Indivior PLC in a research report on Friday, July 29th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Indivior PLC presently has an average rating of “Buy” and a consensus target price of GBX 345.71 ($4.51).
Indivior PLC (LON:INDV) opened at 313.20 on Tuesday. Indivior PLC has a 52-week low of GBX 126.60 and a 52-week high of GBX 365.00. The company’s 50 day moving average price is GBX 318.88 and its 200 day moving average price is GBX 237.86. The company’s market cap is GBX 2.26 billion.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of prescription drugs that are based on buprenorphine for treatment of opioid dependence segment. The Company’s treatment and pipeline focuses on opioid use disorder, alcohol use disorder, overdose rescue and co-morbidities of addiction/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with MarketBeat.com's FREE daily email newsletter.